Covaxin Approved For Emergency Use In 13 Countries Mos For Health Bharati Pravin Pawar

Covaxin Approved For Emergency Use In 13 Countries Mos For Health Bharati Pravin Pawar

By, Admin 2 September 2022

Covaxin Has Been Granted Approval For Emergency Use In 13 Countries As Of January 31, 2022, According To The Who, Said Minister Of State (Mos) For Health Bharati Pravin Pawar In Lok Sabha On February 4.Covaxin Has Been Granted Approval For Emergency Use In 13 Countries As Of January 31, 2022, According To The Who, Said Minister Of State (Mos) For Health Bharati Pravin Pawar In Lok Sabha On February 4. Giving The Details About Covaxin, The Mos For Health Said, "Covaxin Has Been Granted Emergency Use Listing (Eul) By National Regulator Drug Controller General Of India (Dcg(I)) In The Age-Group From 12 To 18 Years On 24Th December 2021."In Her Written Reply, She Mentioned That The Covid-19 Working Group Of National Technical Advisory Group On Immunisation (Ntagi) Recommended Covid-19 Vaccination In Adolescents Aged 15 Years To Less Than 18 Years. "On The Recommendation Of Covid-19 Working Group And Standing Technical Subcommittee Of National Technical Advisory Group On Immunization (Ntagi), Government Of India Has Started Vaccination Of Adolescents Aged 15 Years To Less Than 18 Years From 3Rd January 2022," She Informed The Lok Sabha. She Said That The Grant Of Approval To A Vaccine By Any Country Is A Technical And Scientific Process For Which Data Is To Be Submitted To The Regulator By The Vaccine Manufacturer As Per The Prescribed Rules. Regarding Supplies, She Said That No Specific Information Has Been Brought To Notice By Foreign Companies That They Are Facing Difficulties In The Supply Of Covaxin. "During The Second Surge Of Covid Cases In April, May 2021 In The Country, The Requirements Of National Covid-19 Vaccination Programme Were Prioritized. This May Have Impacted Foreign Commercial Contracts Entered Into By Domestic Vaccine Manufacturers. As Informed By The Ministry Of External Affairs, There Is No Financial Loss Involved Since During The Second Surge Of Covid Pandemic In The Country, Domestic Vaccine Production Was Procured And Utilized In The National Covid-19 Vaccination Programme," She Added. (Ani)

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!